Novartis AG (NYSE:NVS) is reporting second quarter financial results on Tuesday 21st July 2020, before market open.
According to analysts surveyed by Thomson Reuters, NVS is expected to report 2Q20 income of $ 1.35 per share from revenue of $ 11998.80 million.
For the full year, analysts anticipate top line of $ 50267.80 million, while looking forward to income of $ 5.61 per share bottom line.
Previous Quarter Performance
Novartis AG came out with income for the first quarter of $ 1.56 per share, from the revenue of $ 12,283.00 million. The quarterly earnings swell 28.93 percent while revenues grew 10.60 percent compared with the same quarter last year.
Street analysts expected Novartis AG to report income of $ 1.35 per share on revenue of $ 11998.90 million for the first quarter. The bottom line results beat street analysts by $ 0.21 or 15.56 percent, at the same time, top line results outshined analysts by $ 284.10 million or 2.37 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Novartis AG
Stock Performance
According to the previous trading day, closing price of NVS was $ 88.01, representing a 27.22 % increase from the 52 week low of $ 69.18 and a 11.85 % decrease over the 52 week high of $ 99.84.
The company has a market capital of $ 199.01 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”NVS” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The companys Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
